Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): A double-blind, randomised, placebo-controlled trial

The Lancet Neurology

Volumn 14, Issue 12, 2015, Pages 1161-1170

  Trenkwalder, Claudia ^a,b,r   Chaudhuri, K Ray ^c,d   Martinez Martin, Pablo ^e   Rascol, Olivier ^f,g   Ehret, Reinhard ^h,r   Vališ, Martin ^i,j,r   Sátori, Maria ^k,r   Krygowska Wajs, Anna ^l,r   Marti, Maria J ^m   Reimer, Karen ^n,o   Oksche, Alexander ^n,p   Lomax, Mark ^q   DeCesare, Julia ^q   Hopp, Michael ⁿ   Balaz M ^r   Jech, R ^r   Kanovsky P ^r   Pazdera, L ^r   Mach, V ^r   Roubcova D ^r   Kuchar, M ^r   Classen, J ^r   Dressler, D ^r   Muhlack, S ^r   Polzer, U ^r   Schwarz, J ^r   Sommer, M ^r   Kassubek, J ^r   Kuhn A ^r   Eggert, K ^r   Winkler, C ^r   Ceballos Baumann, A ^r   Reichman, H ^r   Csanyi A ^r   Folyovich, A ^r   Levai N ^r   Lajtos, J ^r   Zsolnai, M ^r   Vecsei L ^r   Polrola P ^r   Szczepanska Szerej, A ^r   Honczarenko, A ^r   Kaminska, A ^r   Potemkowski, A ^r   Opala, G ^r   Klimek, A ^r   Rudzinska, M ^r   Albu, V ^r   Enache, C ^r   Falup Pecurariu, C ^r   Mitu, C ^r   Roceanu, A ^r   Balaguer, E ^r   Garcia Moreno, J ^r   Linazasoro, G ^r   Marti Domenech M ^r   Vivancos, F ^r   Kulisevsky, J ^r   Sesar, A ^r   Rodriguez, M ^r   Ellis, S ^r   Molloy, S ^r   Raw, J ^r   Amar, K ^r   Boothman, B ^r   more..

^a Paracelsus Elena Hospital   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d King s College London   (United Kingdom)

^e CARLOS III INSTITUTE OF HEALTH   (Spain)

^f NS Park FCRIN Network and NeuroToul Center of Excellence for Neurodegenerative Disorders   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h Abt Psychiat Neurol P   (Germany)

ⁱ Poliklinika Chocen Neuro   (Czech Republic)

^j UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^k Vaszary Kolos Hospital   (Hungary)

^l JAGIELLONIAN UNIVERSITY   (Poland)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ Mundipharma Research   (Germany)

^o UNIVERSITY OF WITTEN HERDECKE   (Germany)

^p JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^q Mundipharma Research Ltd   (United Kingdom)

^r NONE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE PLUS OXYCODONE; PLACEBO; DELAYED RELEASE FORMULATION; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE;

AGED; ANALGESIA; ARTICLE; ATTENTION DISTURBANCE; CARDIOVASCULAR DISEASE; CHRONIC PAIN; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; CZECH REPUBLIC; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HALLUCINATION; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PARKINSON DISEASE; PERCEPTION DISORDER; PHASE 2 CLINICAL TRIAL; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROMANIA; SECONDARY CARE CENTER; SEXUAL DYSFUNCTION; SLEEP DISORDER; SPAIN; TREATMENT OUTCOME; UNITED KINGDOM; URINARY TRACT DISEASE; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MIDDLE AGED; PAIN;

AGED; ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; OXYCODONE; PAIN; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84946723923     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00243-4     Document Type: Article

References (39)

1. Chaudhuri KR, Schapira AH Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
2. Maass A, Reichmann H Sleep and non-motor symptoms in Parkinson's disease. J Neural Transm 2013, 120:565-569.
3. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26:399-406.
4. Chaudhuri KR, Healy DG, Schapira AH Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
5. Rana AQ, Kabir A, Jesudasan M, Siddiqui I, Khondker S Pain in Parkinson's disease: analysis and literature review. Clin Neurol Neurosurg 2013, 115:2313-2317.
6. Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008, 23:1361-1369.
7. Beiske AG, Loge JH, Ronningen A, Svensson E Pain in Parkinson's disease: prevalence and characteristics. Pain 2009, 141:173-177.
8. Wasner G, Deuschl G Pains in Parkinson disease: many syndromes under one umbrella. Nat Rev Neurol 2012, 8:284-294.
9. Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 2008, 65:1191-1194.
10. Brefel-Courbon C, Grolleau S, Thalamas C, et al. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain 2009, 141:14-18.
11. Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O Emerging analgesic drugs for Parkinson's disease. Expert Opin Emerg Drugs 2012, 17:157-171.
12. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011, 26(suppl 3):S42-S80.
13. Vargas-Schaffer G Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 2010, 56:514-515.
14. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009, 10:35-42.
15. Kaye J, Gage H, Kimber A, Storey L, Trend P Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord 2006, 21:1270-1273.
16. Brock C, Olesen SS, Olesen AE, Frokjaer JB, Andresen T, Drewes AM Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012, 72:1847-1865.
17. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012, 50:360-367.
18. Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011, 20:427-439.
19. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012, 26:50-60.
20. Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer 2015, 23:823-830.
21. Dunlop W, Uhl R, Khan I, Taylor A, Barton G Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012, 15:564-575.
22. Koopmans G, Simpson K, De Andrés J, Lux EA, Wagemans M, Van Megen Y Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives. Curr Med Res Opin 2014, 30:2389-2396.
23. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009, 10:531-543.
24. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010, 64:763-774.
25. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008, 24:3503-3512.
26. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008, 9:1144-1154.
27. Trenkwalder C, Benes H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 2013, 12:1141-1150.
28. Madeo G, Schirinzi T, Natoli S, et al. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. J Neurol 2015, 262:2164-2170.
29. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113:9-19.
30. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011, 17:717-723.
31. Chaudhuri KR, Rizos A, Truyers C, et al. King's Parkinson's Disease (PD) Pain Scale, the first scale for pain in PD: an international validation. Mov Disord 2015, published online June 11. 10.1002/mds.26270.
32. Guideline on data monitoring committees European Medicines Agency, (accessed Sept 10, 2015). http://osp.od.nih.gov/sites/default/files/resources/WC500003635.pdf.
33. Ha AD, Jankovic J Pain in Parkinson's disease. Mov Disord 2012, 27:485-491.
34. Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. Parkinsonism Relat Disord 2013, 19:548-552.
35. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005, 20:1557-1563.
36. Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2011, 26:153-157.
37. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010, 10:12.
38. DePriest AZ, Miller K Oxycodone/naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther 2014, 3:1-15.
39. Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC Neurol 2014, 14:42.